Patients with non-small cell lung cancer (NSCLC) harboring common mutations of the epidermal growth factor receptor (EGFR) are sensitive to EGFR-tyrosine kinase inhibitors (TKI). Although forms of EGFR harboring single uncommon mutations such as G719X or L861Q are thought to be less sensitive to EGFR-TKI, the efficacy of these drugs in patients with double uncommon mutations has remained unclear. We here present an NSCLC patient found to be positive for double uncommon EGFR 
Patients with non-small cell lung cancer (NSCLC) harboring common mutations of the epidermal growth factor receptor (EGFR) are sensitive to EGFR-tyrosine kinase inhibitors (TKI). Although forms of EGFR harboring single uncommon mutations such as G719X or L861Q are thought to be less sensitive to EGFR-TKI, the efficacy of these drugs in patients with double uncommon mutations has remained unclear. We here present an NSCLC patient found to be positive for double uncommon EGFR mutations (G719X and L861Q) by clinical genomic sequencing analysis of a pleural effusion specimen who showed a durable response to the EGFR-TKI afatinib. The Patients who harbor these common mutations manifest a marked response to EGFR-tyrosine kinase inhibitors (TKI), whereas those positive for uncommon EGFR mutations are thought to be less sensitive to Shinichi Kimura and Kentaro Tanaka contributed equally to this work. these drugs. The frequency of such uncommon mutations among individuals with EGFR-mutated NSCLC has been estimated at 4%-13%. 
| MATERIALS AND METHODS
Plasmids encoding YFP-tagged fragments of EGFR-ICD containing single or double mutations were generated as described previously. 
| DISCUSSION
Previous clinical reports have found that patients with NSCLC harboring uncommon mutations of EGFR tend to be less sensitive to reversible (first-generation) EGFR-TKI compared with those positive for common EGFR mutations. 7 However, subset analysis of the LUXLung 3 and LUX-Lung 6 trials showed that the objective response rate for the second-generation EGFR-TKI afatinib was 77.8% and 56.3% in patients with G719X or L861Q mutations of EGFR, respectively. 2 In vitro studies found that EGFR with a single G719X mutation was more sensitive to second-generation than to firstgeneration or third-generation EGFR-TKI, and that EGFR with a single L861Q mutation was sensitive to both second-generation and third-generation EGFR-TKI. 1, 7 These data thus suggest that afatinib is the most appropriate EGFR-TKI for NSCLC harboring uncommon mutations of EGFR. However, the efficacy of afatinib in patients with double uncommon mutations of EGFR has not been clear.
As far as we are aware, the successful treatment of only 1 other patient with double uncommon mutations of EGFR with afatinib has been previously reported. 8 In that report, the inhibitory effect of afa- In conclusion, we here presented the case of a patient harboring double uncommon mutations of EGFR who showed a marked response to afatinib treatment. The efficacy of afatinib for EGFR F I G U R E 2 Sensitivity of Ex19del and Ex19del/T790M mutant forms of epidermal growth factor receptor (EGFR) to EGFRtyrosine kinase inhibitors. HEK293 cells expressing yellow fluorescent protein-EGFR-intracellular domain mutants were exposed to erlotinib or afatinib at the indicated concentrations for 6 h, after which the cells were examined by fluorescence microscopy. Scale bars, 10 μm F I G U R E 3 Sensitivity of epidermal growth factor receptor (EGFR) with single or double uncommon mutations to EGFRtyrosine kinase inhibitors. A, C, HEK293 cells expressing G719A, G719S, L861Q, G719A/L861Q or G719S/L861Q mutant forms of yellow fluorescent protein-EGFRintracellular domain were exposed to erlotinib (A) or afatinib (C) at the indicated concentrations for 6 h and then examined by fluorescence microscopy. Scale bars, 10 μm. B, D, Proportion of cells with fibrillike structures for cells exposed to erlotinib (B) or afatinib (D) as in (A) and (C), respectively harboring such double mutations was confirmed with an assay based on YFP-EGFR-ICD expression.
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